All stock lists
Obsidian Therapeutics, Inc. (NASDAQ:OBX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
13.87+4.26 (+44.43%)
Insider Score
––Not scored
OBX Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
OBX Income Statement
| Fiscal Period | Q1 2026 | Q1 2025 |
|---|---|---|
| Period Ending | Mar 31, 2026 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| SG&A Expense | 4.55 M | 5.48 M |
| R&D Expense | 15.73 M | 21.13 M |
| Operating Expenses | 20.28 M | 26.60 M |
| Operating Income | -20.28 M | -26.60 M |
| Pretax Income | -19.63 M | -24.99 M |
| Tax Provision | 0.00 | 0.00 |
| Net Income | -19.63 M | -24.99 M |
| EPS (Basic) | -0.32 | -0.41 |
| EPS (Diluted) | -0.32 | -0.41 |
| Shares Outstanding | 61.60 M | 61.60 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.